Studies radiotherapy for a few spread cancers, guided by patient data
Observes patients with limited spread of cancer treated with stereotactic radiotherapy.
Plain-language title generated from the registry record
Registry title: The Impact of Radiotherapy on Oligometastatic Cancer
Key facts
- Where
- Albacete, Barcelona, Castellon, Girona, Granada, Lleida, Madrid, Reus, Seville, Terrassa, Valencia, and Zaragoza, SpainSee the 21 sites
Where in Spain
- Complejo Hospitalario Universitario AlbaceteAlbacete, SpainNot yet recruiting
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
- Hospital del MarBarcelona, SpainNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Institut Catala d'OncologiaBarcelona, SpainNot yet recruiting
- Hospital Provincial de CastellónCastellon, SpainNot yet recruiting
- Institut Català d'OncologiaGirona, SpainNot yet recruiting
- Hospital Universitario Virgen de las NievesGranada, SpainNot yet recruiting
- Hospital Universitari Arnau de VilanovaLleida, SpainNot yet recruiting
- Hospital de La LuzMadrid, SpainNot yet recruiting
- Hospital Ruber InternacionalMadrid, SpainNot yet recruiting
- Hospital Universitario HM SanchinarroMadrid, SpainNot yet recruiting
- Hospital Universitario QuirónsaludMadrid, SpainNot yet recruiting
- Hospital Universitario Ramón y CajalMadrid, SpainNot yet recruiting
- Hospital Universitario Rey Juan CarlosMadrid, SpainNot yet recruiting
- Hospital Universitari Sant Joan de ReusReus, SpainTaking people
- Hospital Universitario Virgen MacarenaSeville, SpainNot yet recruiting
- Hospital de TerrassaTerrassa, SpainNot yet recruiting
- Hospital Clinico Universitario de ValenciaValencia, SpainNot yet recruiting
- Hospital General Univesitario de ValenciaValencia, SpainNot yet recruiting
- Hospital Universitari Miguel ServetZaragoza, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut Investigacio Sanitaria Pere Virgili
- Trial code
- NCT05933876
- Record updated
- 18 November 2024
- Original description
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.Read full original descriptionShow less
Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Inclusion: Histologic confirmation of primary tumor: breast, prostate, lung, colorectal; 18 years old or older; Up to five metastases located in the bone, lung, node, liver or brain; Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.
Exclusion: Previous radiotherapy in the same anatomic location; Non-melanoma skin cancer; Presence of vascular collagen disease; Pregnancy or lactation at the time of inclusion.